Organisation paid for research Program year 2025 Source: CMS Open Payments

Clearwater Cardiovascular

Neither a doctor nor a teaching hospital

Research payments

$752,276

39 payments

Through program year 2025, Clearwater Cardiovascular is reported as receiving $752,276 in research payments, across 39 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$334,291	7
2024	Research	$233,469	11
2023	Research	$73,953	6
2022	Research	$47,264	7
2021	Research	$63,300	8

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $737,676 33 payments
HeartFlow, Inc. $14,600 6 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $415,836 12 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $210,786 14 payments
A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $73,953 6 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $37,101 1 payment
100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 424 PRECISE $14,600 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.